We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Amgen (AMGN - Free Report) was up +1.22% at $331.39. The stock exceeded the S&P 500, which registered a gain of 0.64% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.52%.
Heading into today, shares of the world's largest biotech drugmaker had lost 3.01% over the past month, lagging the Medical sector's gain of 2.25% and the S&P 500's gain of 3%.
The upcoming earnings release of Amgen will be of great interest to investors. It is anticipated that the company will report an EPS of $4.73, marking a 10.92% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $9.47 billion, indicating a 4.2% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $21.27 per share and a revenue of $36.36 billion, demonstrating changes of +7.21% and +8.78%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Amgen is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Amgen's current valuation metrics, including its Forward P/E ratio of 15.39. This expresses a discount compared to the average Forward P/E of 18.56 of its industry.
Also, we should mention that AMGN has a PEG ratio of 3.11. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.69 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 90, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Amgen (AMGN - Free Report) was up +1.22% at $331.39. The stock exceeded the S&P 500, which registered a gain of 0.64% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.52%.
Heading into today, shares of the world's largest biotech drugmaker had lost 3.01% over the past month, lagging the Medical sector's gain of 2.25% and the S&P 500's gain of 3%.
The upcoming earnings release of Amgen will be of great interest to investors. It is anticipated that the company will report an EPS of $4.73, marking a 10.92% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $9.47 billion, indicating a 4.2% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $21.27 per share and a revenue of $36.36 billion, demonstrating changes of +7.21% and +8.78%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Amgen is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Amgen's current valuation metrics, including its Forward P/E ratio of 15.39. This expresses a discount compared to the average Forward P/E of 18.56 of its industry.
Also, we should mention that AMGN has a PEG ratio of 3.11. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.69 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 90, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.